Endocrinology Genetics Panel
The Endocrinology Genetics Panel is a comprehensive, targeted Next-Generation Sequencing (NGS) assay designed to profile germline and somatic mutations across genes regulating hormone synthesis, receptor signaling, and endocrine organ development (pituitary, thyroid, parathyroid, adrenal, pancreas, and gonads). By deciphering the molecular etiology of monogenic diabetes, hereditary endocrine tumor syndromes, congenital adrenal/thyroid disorders, and growth/pubertal anomalies, this panel enables precise molecular diagnosis, tailored hormone/pharmacotherapy, and proactive family risk management.
Key Features & Advantages
- Definitive Molecular Diagnosis: Resolves complex, overlapping metabolic and endocrine phenotypes across multiple hormonal axes.
- Hereditary Cancer & Tumor Risk Management: Identifies familial tumor predispositions such as Multiple Endocrine Neoplasia (MEN1, MEN2A/2B) prior to lesion development, guiding prophylactic interventions or targeted surveillance.
- Monogenic Diabetes (MODY) Differentiation: Accurately distinguishes MODY from Type 1 or Type 2 Diabetes, enabling transition from lifelong insulin injections to targeted oral sulfonylureas where applicable.
- Cascade Family Screening: Identifies pathogenic variants in the proband to facilitate rapid, cost-effective screening of first-degree relatives.
Endocrinology NGS Panel vs. Conventional Hormone & Biochemical Assays
| Feature | Endocrinology Genetics Panel (NGS) | Standard Hormone & Biochemical Assays |
| Diagnostic Scope | Genes encoding hormones, receptors, and enzymes | Fluctuating serum hormone levels and metabolites |
| Etiological Resolution | High (Pinpoints receptor insensitivity, enzyme defect, or tumor risk) | Limited (Reflects hormone excess/deficiency without root cause) |
| Diurnal Fluctuation Risk | Zero (Genomic DNA remains constant) | High (Vulnerable to stress, circadian rhythm, diet, and timing) |
| Pre-Symptomatic Detection | Yes (Identifies risk before endocrine axis collapse) | No (Detects alterations only after biochemical disruption) |
| Therapeutic Precision | Genotype-guided targeted therapy & MODY management | Symptom-driven, generalized hormone replacement |
Key Applications
- Familial Endocrine Tumor Syndromes: Comprehensive profiling for Multiple Endocrine Neoplasia (MEN1, MEN2A, MEN2B), Familial Medullary Thyroid Carcinoma (FMTC), and Hereditary Pheochromocytoma/Paraganglioma.
- Monogenic Diabetes & Hypoglycemia: Screening for Maturity-Onset Diabetes of the Young (MODY), Neonatal Diabetes, and Congenital Hyperinsulinism.
- Adrenal & Thyroid Disorders: Genetic evaluation of Congenital Adrenal Hyperplasia (CAH), Primary Aldosteronism, Thyroid Hormone Resistance, and Congenital Hypothyroidism.
- Growth, Puberty & Sexual Development Disorders: Profiling Hypogonadotropic Hypogonadism (Kallmann Syndrome), Delayed/Precocious Puberty, and Disorders of Sex Development (DSD).
The Nucleus Genetics Advantage: Combining ultra-deep NGS target enrichment panels aligned with Endocrine Society guidelines, advanced bioinformatic algorithms, and multidisciplinary curation by medical geneticists and endocrinologists, we transform complex genomic data into actionable clinical reports.
Get Information About This Service
Our expert team is ready to answer your questions and offer tailored solutions.
Contact Form →